DUBLIN, Nov 12 (Reuters) – Most of Ireland’s big corporate taxpayers have so far escaped the direct impact of U.S. tariffs, but American trade policies have made the outlook for this critical source of government revenue increasingly uncertain, Ireland’s fiscal watchdog said.
Sign up here.
The Irish Fiscal Advisory Council (IFAC) noted on Wednesday that the pharmaceutical and technology sectors, which together represent about 87% of corporate tax payments from U.S.-owned firms, had avoided U.S. tariffs so far.
PHARMA EXPORTS SURGED AHEAD OF EXPECTED TARIFFS
It added that the data also pointed to a structural increase in exports of an active ingredient used in weight-loss drugs, boosting short-term corporate tax receipts.
However, IFAC warned the sector’s outlook remained “very uncertain”.
Risks include the long-term objective of the tariffs to encourage more pharma manufacturing in the United States.
“Corporation tax revenues from pharma could go up by a lot or down by a lot.”
While there is a clear risk corporate tax could decline in other manufacturing sectors such as drinks and medical devices likely to be directly affected by tariffs, they accounted for just 4% of Irish corporate revenues in 2024, IFAC added.
Reporting by Padraic Halpin
Editing by Mark Potter
Our Standards: The Thomson Reuters Trust Principles.
